Literature DB >> 10974451

Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters.

B Rau1, P Wust, W Tilly, J Gellermann, C Harder, H Riess, V Budach, R Felix, P M Schlag.   

Abstract

PURPOSE: Preoperative radiochemotherapy (RCT) is a widely used means of treatment for patients suffering from primary, locally advanced, or recurrent rectal cancer. We evaluated the efficacy of treatment due to additional application of regional hyperthermia (HRCT) to this conventional therapy regime in a Phase II study, employing the annular phased-array system BSD-2000 (SIGMA-60 applicator). The clinical results of the trial were encouraging. We investigated the relationship between a variety of thermal and clinical parameters in order to assess the adequacy of thermometry, the effectiveness of hyperthermia therapy, and its potential contribution to clinical endpoints. METHODS AND MATERIALS: A preoperative combination of radiotherapy (1.8 Gy for 5 days a week, total dose 45 Gy applied over 5 weeks) and chemotherapy (low-dose 5-fluorouracil [5-FU] plus leucovorin in the first and fourth week) was administered to 37 patients with primary rectal cancer (PRC) and 18 patients with recurrent rectal cancer (RRC). Regional hyperthermia (RHT) was applied once a week prior to the daily irradiation fraction of 1.8 Gy. Temperatures were registered along rectal catheters using Bowman thermistors. Measurement points related to the tumor were specified after estimating the section of the catheter in near contact with the tumor. Three patients with local recurrence after abdominoperineal resection, had their catheters positioned transgluteally under CT guidance, where the section of the catheter related to the tumor was estimated from the CT scans. Index temperatures (especially T(max), T(90)) averaged over time, cumulative minutes (cum min) (here for T(90) > reference temperature 40.5 degrees C), and equivalent minutes (equ min) (with respect to 43 degrees C) were derived from repetitive temperature-position scans (5- to 10-min intervals) utilizing software specially developed for this purpose on a PC platform. Using the statistical software package SPSS a careful analysis was performed, not only of the variance of thermal parameters with respect to clinical criteria such as toxicity, response, and survival but also its dependency on tumor characteristics.
RESULTS: The rate of resectability (89%) and response (59%) were high for the PRC group, and a clear positive correlation existed between index temperatures (T(90)) and thermal doses (cum min T(90) >/= 40.5 degrees C). Even though the overall 5-year survival was encouraging (60%) and significantly associated with response, there was no statistically significant relationship between temperature parameters and long-term survival for this limited number of patients. However, nonresectable tumors with higher thermal parameters (especially cum min T(90) >/= 40.5 degrees C) had a tendency for better overall survival. We found even higher temperatures in patients with recurrences (T(90) = 40.7 degrees C versus T(90) = 40.2 degrees C). However, these conditions for easier heating did not involve a favorable clinical outcome, since surgical resectability (22%) and response rate (28%) for the RRC group were low. We did not notice any other dependency of thermal parameters to a specific tumor or patient characteristics. Finally, neither acute toxicity (hot spots) induced by hyperthermia or RCT nor perioperative morbidity were correlated with temperature-derived parameters. Only a higher probability for the occurrence of hot spots was found during treatment with elevated power levels.
CONCLUSION: In this study with two subgroups, i.e., patients with PRC (n = 37) and RRC (n = 18), there exists a positive interrelationship between thermal parameters (such as T(90), cum min T(90) >/= 40,5 degrees C) and clinical parameters concerning effectiveness. Additional hyperthermia treatment does not seem to enhance toxicity or subacute morbidity. Procedures to measure temperatures and to derive thermal parameters, as well as the hyperthermia technique itself appear adequate enough to classify heat treatments in

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974451     DOI: 10.1016/s0360-3016(00)00650-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

2.  Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.

Authors:  Qing-Guo Fu; Fan-Dong Meng; Xiao-Dong Shen; Ren-Xuan Guo
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

Review 3.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

4.  Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology.

Authors:  Holger Amthauer; Timm Denecke; Beate Rau; Bert Hildebrandt; Michael Hünerbein; Juri Ruf; Ulrike Schneider; Matthias Gutberlet; Peter M Schlag; Roland Felix; Peter Wust
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

5.  Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice.

Authors:  Erin B Dickerson; Erik C Dreaden; Xiaohua Huang; Ivan H El-Sayed; Hunghao Chu; Sujatha Pushpanketh; John F McDonald; Mostafa A El-Sayed
Journal:  Cancer Lett       Date:  2008-06-09       Impact factor: 8.679

6.  Surface plasmon-enhanced Ag/CuS nanocomposites for cancer treatment.

Authors:  Chang Yang; Lun Ma; Xiaoju Zou; Guangya Xiang; Wei Chen
Journal:  Cancer Nanotechnol       Date:  2013-05-18

7.  The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.

Authors:  Nathalie van den Tempel; Charlie Laffeber; Hanny Odijk; Wiggert A van Cappellen; Gerard C van Rhoon; Martine Franckena; Roland Kanaar
Journal:  Oncotarget       Date:  2017-07-04

Review 8.  Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.

Authors:  Niloy R Datta; H Petra Kok; Hans Crezee; Udo S Gaipl; Stephan Bodis
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

9.  Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.

Authors:  Michael Hader; Deniz Pinar Savcigil; Andreas Rosin; Philipp Ponfick; Stephan Gekle; Martin Wadepohl; Sander Bekeschus; Rainer Fietkau; Benjamin Frey; Eberhard Schlücker; Udo S Gaipl
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

10.  Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.

Authors:  Arndt-Christian Müller; Daniel Zips; Vanessa Heinrich; Ulf Lamprecht; Otilia Voigt; Susen Burock; Volker Budach; Peter Wust; Pirus Ghadjar
Journal:  Radiat Oncol       Date:  2015-07-08       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.